Home › Funds › Delaney Capital Management Ltd. › EPRX
Delaney Capital Management Ltd. position in EPRX
Eupraxia Pharmaceuticals Inc · Health Care
Delaney Capital Management Ltd. reported holding 112,400 shares of EPRX (Eupraxia Pharmaceuticals Inc) in its Q3 2026 13F filing — a position valued at US$1.0M, representing 0.16% of its reported portfolio and ranking #32 among its reported holdings. Delaney Capital Management Ltd. has disclosed EPRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Delaney Capital Management Ltd.'s EPRX position evolved
Delaney Capital Management Ltd. first disclosed a stake in EPRX in Q4 2025 at 119,400 shares (US$899K). The position peaked in Q3 2026 at 112,400 shares, worth US$1.0M. Across 4 filings, Delaney Capital Management Ltd. increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 112,400 shares valued at US$1.0M — a reduction of -4,800 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 119.40K | $899.03K | New |
| Q1 2026 | 119.40K | $860.02K | Hold |
| Q2 2026 | 117.20K | $767.86K | Reduce |
| Q3 2026 | 112.40K | $1.03M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EPRX and 13F data
EPRX (Eupraxia Pharmaceuticals Inc) is a Health Care company. 70 other funds we track also report a position in EPRX — the largest reported positions include Vivo Capital, LLC (US$12.3M), PFM Health Sciences, LP (US$8.0M), GREAT POINT PARTNERS LLC (US$7.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EPRX
- Vivo Capital, LLC 1.35M sh · $12.29M · Q3 2026
- PFM Health Sciences, LP 1.21M sh · $8.00M · Q2 2026
- GREAT POINT PARTNERS LLC 1.20M sh · $7.93M · Q2 2026
- Ikarian Capital, LLC 809.74K sh · $5.35M · Q2 2026
- Redmile Group, LLC 611.40K sh · $4.04M · Q2 2026
- Seven Fleet Capital Management LP 610.78K sh · $4.04M · Q2 2026
- Aisling Capital Management LP 325.00K sh · $2.96M · Q3 2026
- Velan Capital Investment Management LP 352.00K sh · $2.33M · Q2 2026
- Ally Bridge Group (NY) LLC 252.18K sh · $1.67M · Q2 2026
- Lynx1 Capital Management LP 10.00K sh · $66.10K · Q2 2026
More on Delaney Capital Management Ltd.
FAQ
How long has Delaney Capital Management Ltd. held EPRX?
Delaney Capital Management Ltd. has disclosed EPRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Delaney Capital Management Ltd.'s current position in EPRX?
As of Q3 2026, Delaney Capital Management Ltd. holds 112.40K shares of EPRX (Eupraxia Pharmaceuticals Inc), valued at $1.03M, representing 0.16% of its reported portfolio and ranking #32.
Has Delaney Capital Management Ltd. been buying or selling EPRX?
In the latest 13F filing (Q3 2026), Delaney Capital Management Ltd. reduced its position in EPRX. The position peaked in Q3 2026 at 112.40K shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Vivo Capital, LLC, PFM Health Sciences, LP, GREAT POINT PARTNERS LLC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.